BRAHMS-CgA-II-prostate-cancer

B·R·A·H·M·S CgA II KRYPTOR for early identification of treatment-emergent neuroendocrine prostate cancer (NEPC)

Use serum Chromogranin A (CgA) on B·R·A·H·M·S KRYPTOR instruments as a tool in early detection of prostate cancer transition during monitoring of all your patients under hormonal therapy. The fully automated immunoassay for Chromogranin A is not only indicated in neuroendocrine tumors but also provides a tool to early identify neuroendocrine differentiated prostate cancer and ADT resistance.

Find out below how our product can help you in the clinical care of your patients or contact us directly.

Contact us >

    

CgA in prostate cancer – Videos

                    

                   Expert interviews – Summary

 

                   Expert interviews – Long version

More information on B·R·A·H·M·S CgA ll KRYPTOR in prostate cancer

Download brochures





Contact us >

References

Bray, F., et al., CA Cancer J Clin, 2018. 68(6): p. 394–424.

Beltran, H., et al., Cancer Discov, 2011. 1(6): p. 487–95.

Tritschler, S., et al., Pathologe, 2018. 39(4): p. 333–343.

Tarle, M., M.Z. Ahel, and K. Kovacic, Anticancer Res, 2002. 22(4): p. 2525–9.

Berruti, A., et al., J Urol, 2007. 178(3 Pt 1): p. 838-43; quiz 1129.

Aggarwal, R.R., F.Y. Feng, and E.J. Small, Oncology (Williston Park), 2017. 31(6): p. 467–74.

Hirano, D., et al., Scand J Urol Nephrol, 2007. 41(4): p. 297–301.2.

Sciarra, A., et al., Urol Int, 2009. 82(2): p. 147– 51.